Cat. No. | Product name | CAS No. |
DC66650 |
CP-LC-0729
Featured
Lipid CP-LC-0729 is an ionizable cationic amino lipid derived from homocysteine, a naturally occurring amino acid. This lipid has demonstrated an efficient delivery and high protein expression of different kinds of RNA (mRNA, cRNA and saRNA) in vivo, with no signs of toxicity. |
3040858-60-1 |
DC66651 |
CP-LC-0743
Featured
Lipid CP-LC-0743 is an ionizable cationic amino lipid derived from homocysteine, a naturally occurring amino acid. This lipid has demonstrated an efficient delivery and high protein expression of different kinds of RNA (mRNA, cRNA and saRNA) in vivo, with no signs of toxicity. |
3040858-73-6 |
DC66652 |
CP-LC-0867
Featured
Lipid CP-LC-0867 is an ionizable cationic amino lipid derived from homocysteine, a naturally occurring amino acid. This lipid has demonstrated an efficient delivery and high protein expression of different kinds of RNA (mRNA, cRNA and saRNA) in vivo, with no signs of toxicity. |
3040858-96-3 |
DC66653 |
C9-200
Featured
C9-200 is an ionizable cationic lipid that has been used in the formation of lipid nanoparticles (LNPs).1 LNPs containing C9-200 and encapsulating mRNA encoding erythropoietin (EPO) increase serum EPO levels in mice. LNPs containing C9-200 and encapsulating mRNA encoding the Cas9 nuclease and small-guide RNA (sgRNA) targeting transthyretin (TTR) induce 3-fold higher hepatic insertion and deletion (indel) formation than LNPs containing C12-200 (Item No. 36699) and encapsulating mRNA encoding Cas9 in mice. |
|
DC66654 |
Lipid N2-3L
Featured
Lipid N2-3L is an ionizable cationic lipid (pKa = 8.99) that has been used in the generation of supramolecular lipid nanoparticles (SMLNPs) encapsulating mRNA for use in vitro and in vivo.1 SMLNPs containing lipid N2-3L and encapsulating a luciferase reporter accumulate at the site of injection and in the draining lymph nodes of mice. Lipid N2-3L-containing SMLNPs encapsulating ovalbumin mRNA and the toll-like receptor 7/8 (TLR7/8) agonist R-848 (Item No. 14806) as an adjuvant promote dendritic cell maturation and antigen presentation, reduce tumor volume, and increase survival in an MC-38-OVA murine model of colon cancer. |
2924606-55-1 |
DC66655 |
YHS-12
Featured
YHS-12 is an ionizable cationic lipid (pKa = 6.506) that has been used in the generation of lipid nanoparticles (LNPs) for the delivery of siRNA and mRNA in vitro and in vivo.1 LNPs containing YHS-12 and the macrophage targeting peptide CRVLRSGSC and encapsulating mRNA encoding chimeric antigen receptor targeting methicillin-resistant S. aureus (MRSA) and siRNA targeting caspase-11 increase the phagocytosis rate of MRSA in RAW 264.7 macrophages and primary mouse bone marrow-derived macrophages (BMDMs). Intravenous administration of these LNPs decreases blood bacterial burden and increases survival in a model of sepsis using cyclophosphamide-induced immunosuppressed mice. |
2959463-68-2 |
DC66656 | Antitope patent anti-CTLA4 Featured | |
DC66657 |
Tremelimumab
Featured
Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research. |
745013-59-6 |
DC66658 |
Vunakizumab
Featured
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis. |
1792181-33-9 |
DC66659 |
Antibodies
Featured
Perakizumab (RG4934) is a humanized IgG1κ monoclonal antibody against IL-17A (Interleukin Related). Perakizumab can be uesd for the research of autoimmune diseases, such as psoriatic arthritis. |
89957-37-9 |
DC66660 |
Netakimab
Featured
Netakimab is an anti-IL-17 monoclonal antibody. Nerelimomab can be used for research of ankylosing spondylitis, psoriatic arthritis, moderate-to-severe plaque psoriasis. |
1796570-08-5 |
DC66661 | Med. Bio. Labs patent anti-CXADR Featured | |
DC66662 | Anti-CXCL8 Featured | |
DC66663 | Anti-CYR61 Featured | |
DC66664 | Dragonfly patent anti-DLL3 Featured | |
DC66665 |
Begelomab
Featured
Begelomab (SAND-26) is a murine IgG2b monoclonal antibody against DPP-4/CD26. Begelomab can be used for the research of severe refractory idiopathic inflammatory myopathy. |
1403744-56-8 |
DC66666 | Citatuzumab Featured | |
DC66667 | MEDI-547 Featured | |
DC66668 | Sanofi Aventis patent anti-EphA2 Featured | |
DC66669 |
Disitamab
Featured
Disitamab (RC48-0) is a humanized monoclonal antibody targeting HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (Disitamab vedotin (HY-P9985)). |
2185868-98-6 |
DC66670 |
Tisotumab
Featured
Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody targets tissue factor (TF). Tisotumab can be used for the research of solid tumors. |
1418628-81-5 |
DC66671 | TNX-832 Featured |